
CLAIMS

1. A peptide nucleic acid derivative represented by **Formula I**, or a pharmaceutically acceptable salt thereof:

[Formula I]



wherein,

n is an integer between 10 and 21;

the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 16-mer pre-mRNA sequence of [(5' → 3') CAUAUAUGGUGAGUAU] in the human MMP-1 pre-mRNA;

the compound of **Formula I** is fully complementary to the human MMP-1 pre-mRNA, or partially complementary to the human MMP-1 pre-mRNA with one or two mismatches;

S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ···, T_{n-1}, and T_n independently represent hydrido, deuterido, substituted or non-substituted alkyl, or substituted or non-substituted aryl radical;

X and Y independently represent hydrido, deuterido, formyl [H-C(=O)-], aminocarbonyl [NH_2-C(=O)-], aminothiocarbonyl [NH_2-C(=S)-], substituted or non-substituted alkyl, substituted or non-substituted aryl, substituted or non-substituted alkyloxy, substituted or non-substituted aryloxy, substituted or non-substituted alkylacyl, substituted or non-substituted arylacyl, substituted or non-substituted alkyloxycarbonyl, substituted or non-substituted aryloxycarbonyl, substituted or non-substituted alkylaminocarbonyl, substituted or non-substituted arylaminocarbonyl, substituted or non-substituted alkylaminothiocarbonyl, substituted or non-substituted arylaminothiocarbonyl, substituted or non-substituted alkyloxythiocarbonyl, substituted or non-substituted aryloxythiocarbonyl, substituted or non-substituted alkylsulfonyl, substituted or non-substituted arylsulfonyl, substituted or non-substituted alkylphosphonyl, or substituted or non-substituted arylphosphonyl radical;

Z represents hydrido, deuterido, hydroxy, substituted or non-substituted alkyloxy, substituted or non-substituted aryloxy, substituted or non-substituted amino, substituted or non-substituted alkyl, or substituted or non-substituted aryl radical;

B_1, B_2, ···, B_{n-1}, and B_n are independently selected from natural nucleobases including

adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases; and,

at least four of B_1, B_2, ···, B_{n-1}, and B_n are independently selected from unnatural nucleobases with a substituted or non-substituted amino radical covalently linked to the nucleobase moiety.

2. The peptide nucleic acid derivative according to claim 1, or a pharmaceutical salt thereof:

wherein,

n is an integer between 10 and 21;

the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 16-mer pre-mRNA sequence of [(5' → 3') CAUAUAUGGUGAGUAU] in the human MMP-1 pre-mRNA;

the compound of **Formula I** is fully complementary to the human MMP-1 pre-mRNA, or partially complementary to the human MMP-1 pre-mRNA with one or two mismatches;

S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ···, T_{n-1}, and T_n independently represent hydrido, deuterido radical;




X and Y independently represent hydrido, deuterido, formyl [H-C(=O)-], aminocarbonyl [NH_2-C(=O)-], aminothiocarbonyl [NH_2-C(=S)-], substituted or non-substituted alkyl, substituted or non-substituted aryl, substituted or non-substituted alkyloxy, substituted or non-substituted aryloxy, substituted or non-substituted alkylacyl, substituted or non-substituted arylacyl, substituted or non-substituted alkyloxycarbonyl, substituted or non-substituted aryloxycarbonyl, substituted or non-substituted alkylaminocarbonyl, substituted or non-substituted arylaminocarbonyl, substituted or non-substituted alkylaminothiocarbonyl, substituted or non-substituted arylaminothiocarbonyl, substituted or non-substituted alkyloxythiocarbonyl, substituted or non-substituted aryloxythiocarbonyl, substituted or non-substituted alkylsulfonyl, substituted or non-substituted arylsulfonyl, substituted or non-substituted alkylphosphonyl, or substituted or non-substituted arylphosphonyl radical;

Z represents hydrido, hydroxy, substituted or non-substituted alkyloxy, substituted or non-substituted aryloxy, or substituted or non-substituted amino radical;

B_1, B_2, ···, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases;

at least four of B_1, B_2, ···, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II**, **Formula III**, or **Formula IV**:

[Formula II] **[Formula III]** **[Formula IV]**






wherein,

R_1, R_2, R_3, R_4, R_5 and R_6 are independently selected from hydrido and substituted or non-substituted alkyl radical;

L_1, L_2 and L_3 are a covalent linker represented by **Formula V** covalently linking the basic amino group to the nucleobase moiety:

[Formula V]



wherein,

Q_1 and Q_m are substituted or non-substituted methylene ($-CH_2-$) radical, and Q_m is directly linked to the basic amino group;

Q_2, Q_3, $\cdots$, and Q_{m-1} are independently selected from substituted or non-substituted methylene, oxygen (-O-), sulfur (-S-), and substituted or non-substituted amino radical [-N(H)-, or -N(substituent)-]; and,

m is an integer between 1 and 15.

3. The peptide nucleic acid derivative according to claim 2, or a pharmaceutical salt thereof:

wherein,

n is an integer between 11 and 16;

the compound of **Formula I** possesses at least a 10-mer complementary overlap with

the 16-mer pre-mRNA sequence of [(5' → 3') CAUAUAUGGUGAGUAU] in the human MMP-1 pre-mRNA;

the compound of **Formula I** is fully complementary to the human MMP-1 pre-mRNA;

S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ···, T_{n-1}, and T_n are hydrido radical;

X and Y independently represent hydrido, substituted or non-substituted alkylacyl, or substituted or non-substituted alkyloxycarbonyl radical;

Z represents substituted or non-substituted amino radical;

B_1, B_2, ···, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases;

at least five of B_1, B_2, ···, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II**, **Formula III**, or **Formula IV**;

R_1, R_2, R_3, R_4, R_5 and R_6 are hydrido radical;

Q_1 and Q_m are methylene radical, and Q_m is directly linked to the basic amino group;

Q_2, Q_3, ···, and Q_{m-1} are independently selected from methylene and oxygen radical; and,

m is an integer between 1 and 9.

4. The peptide nucleic acid derivative according to claim 3, or a pharmaceutical salt thereof:

wherein,

n is an integer between 11 and 16;

the compound of **Formula I** possesses at least a 10-mer complementary overlap with the 16-mer pre-mRNA sequence of [(5' → 3') CAUAUAUGGUGAGUAU] in the human MMP-1 pre-mRNA;

the compound of **Formula I** is fully complementary to the human MMP-1 pre-mRNA;

S_1, S_2, ···, S_{n-1}, S_n, T_1, T_2, ···, T_{n-1}, and T_n are hydrido radical;

X is hydrido radical;

Y represents substituted or non-substituted alkyloxycarbonyl radical;

Z represents substituted or non-substituted amino radical;

B_1, B_2, ···, B_{n-1}, and B_n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases;

at least five of B_1, B_2, ···, B_{n-1}, and B_n are independently selected from unnatural nucleobases represented by **Formula II**, **Formula III**, or **Formula IV**;

R_1, R_2, R_3, R_4, R_5 and R_6 are hydrido radical;

L_1 represents $-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_2-$, $-CH_2-O-(CH_2)_3-$, $-CH_2-O-(CH_2)_4-$, or $-CH_2-O-(CH_2)_5-$ with the right end is directly linked to the basic amino group; and,

L_2 and L_3 are independently selected from $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_3-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_3-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$, and $-(CH_2)_8-$ with the right end is directly linked to the basic amino group.

5. The peptide nucleic acid derivative according to claim 4, which is a peptide nucleic acid derivative provided below, or a pharmaceutically acceptable salt thereof:


(N→C) Fethoc-TA(6)C-TCA(6)-CC(1O2)A(6)-TA(6)T-A(6)T-NH_2

wherein,


A, T, and C are monomers of peptide nucleic acid with a natural nucleobase of adenine, thymine, and cytosine, respectively;

C(pOq) and A(p) are monomers of peptide nucleic acid with an unnatural nucleobase represented by **Formula VI** and **Formula VII**, respectively;

[Formula VI]



[Formula VII]



wherein,

p and q are integers and p is 1 or 6, and q is 2; and,

"Fethoc-" is the abbreviation for "[2-(9-fluorenyl)ethyl-1-oxy]carbonyl".

6. A method to treat diseases or conditions associated with the human MMP-1 gene transcription, comprising the administration of the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof to a subject.

7. A method to treat skin aging, comprising the administration of the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof to a subject.

8. A pharmaceutical composition for treating diseases or conditions associated with human MMP-1 gene transcription, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

9. A cosmetic composition for treating diseases or conditions associated with human MMP-1 gene transcription, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition for treating skin aging, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.

11. A cosmetic composition for treating skin aging, comprising the peptide nucleic acid derivative according to claim 1, or a pharmaceutically acceptable salt thereof.